ACADIA Pharmaceuticals
ISIN US0042251084
|WKN 603035
Overview
Description
ACADIA Pharmaceuticals, Inc. befasst sich mit der Entwicklung und Vermarktung von Arzneimitteln für Erkrankungen des zentralen Nervensystems. Zu seinen Produkten gehört Nuplazid, das zur Behandlung von Halluzinationen und Wahnvorstellungen im Zusammenhang mit der Psychose der Parkinson-Krankheit eingesetzt wird. Das Unternehmen wurde am 16. Juli 1993 von Mark R. Brann gegründet und hat seinen Hauptsitz in San Diego, CA.
Gesundheitswesen Biopharmazeutische Produkte Systemspezifische Biopharmazeutika USA
Financials
Key metrics
| Market capitalisation, EUR | 2.230,97 Mio. |
| EPS, EUR | 1,26 |
| P/B ratio | 3,32 |
| P/E ratio | 10,73 |
| Dividend yield | 0,00% |
Income statement (2024)
| Revenue, EUR | 885,46 Mio. |
| Net income, EUR | 209,35 Mio. |
| Profit margin | 23,64% |
What ETF is ACADIA Pharmaceuticals in?
There are 29 ETFs which contain ACADIA Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of ACADIA Pharmaceuticals is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
